Royal Bank of Canada’s China SXT Pharmaceuticals SXTC Stock Holding History

Royal Bank of Canada’s Portfolio SXTC Stock Details SXTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$0	Buy	13 +8	+160%	+$205	﹤0.01%	7670
2025 Q4	$1K	Buy	+5	New	+$1.08K	﹤0.01%	7048
2021 Q3	–	Hold	0	–	-$1K	–	7858
2021 Q2	–	Hold	0	–	–	–	7345
2021 Q1	–	Hold	0	–	–	–	7324
2020 Q1	–	Hold	0	–	–	–	7005
2019 Q4	–	Hold	0	–	–	–	7103
2019 Q3	–	Hold	0	–	–	–	7096
2019 Q2	–	Hold	0	–	–	–	7163

Other funds holding SXTC

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

CIAM

Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Royal Bank of Canada's SXTC Position: Q1 2026 in Review

Royal Bank of Canada increased its China SXT Pharmaceuticals (SXTC) stake by 160% in Q1 2026, buying an estimated $205 and bringing the position to 13 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #7670.

Royal Bank of Canada first reported a position in SXTC in Q4 2025 and has held it in 2 quarters since. The position peaked at $1K in Q4 2025. 4 funds tracked by Wall St. Rank hold SXTC as of Q1 2026.

Royal Bank of Canada held 13 shares of China SXT Pharmaceuticals worth $0 as of Q1 2026.
Royal Bank of Canada bought 8 China SXT Pharmaceuticals shares in Q1 2026, an estimated $205.
China SXT Pharmaceuticals made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #7670 holding.
Royal Bank of Canada first reported a position in China SXT Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
Royal Bank of Canada's China SXT Pharmaceuticals position peaked at $1K in Q4 2025.
4 funds tracked by Wall St. Rank held China SXT Pharmaceuticals as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.